Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Market Closed 11-06 16:00:00 EST

4.65

+0.20

+4.49%

盘后4.65

+0.000.00%

19:57 EST

High4.70	Low4.46	Vol3.06M
Open4.53	D1 Closing4.45	Amplitude5.39%
Mkt Cap839.37M	Tradable Cap539.40M	Total Shares180.51M
T/O14.08M	T/O Rate2.64%	Tradable Shares116.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":4.65,"timestamp":1793998800000,"preClose":4.45,"halted":0,"volume":3059122,"hourTrading":{"tag":"盘后","latestPrice":4.65,"preClose":4.65,"latestTime":"19:57 EST","volume":8719,"amount":40132.0141,"timestamp":1794013022994,"change":0,"changeRate":0,"amplitude":0.036559},"delay":0,"changeRate":0.04494382022471914,"floatShares":115999999,"shares":180510658,"eps":-1.085332,"marketStatus":"Market Closed","change":0.2,"latestTime":"11-06 16:00:00 EST","open":4.53,"high":4.695,"low":4.455,"amount":14082676.692541601,"amplitude":0.053933,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.085332,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794214800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":4.45,"preHourTrading":{"tag":"盘前","latestPrice":4.53,"preClose":4.45,"latestTime":"09:29 EST","volume":12661,"amount":57039.3698996,"timestamp":1793975399517,"change":0.08,"changeRate":0.017978,"amplitude":0.079573},"postHourTrading":{"tag":"盘后","latestPrice":4.65,"preClose":4.65,"latestTime":"19:57 EST","volume":8719,"amount":40132.0141,"timestamp":1794013022994,"change":0,"changeRate":0,"amplitude":0.036559},"volumeRatio":0.638347,"impliedVol":1.1688,"impliedVolPercentile":0.6614},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2679183074","title":"Prime Medicine Shares Hit 52-Week High After Dosing Begins in PM577a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2679183074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679183074?lang=en_us&edition=fundamental","pubTime":"2026-10-29 01:53","pubTimestamp":1793209980,"startTime":"0","endTime":"0","summary":"Prime Medicine shares rose after the company said the first patient has been dosed in a Phase 1/2 clinical trial of PM577a, an investigational in vivo prime editor for H1069Q-mutated Wilson disease.The stock was 21% higher, at $5.27, on Wednesday, just off its 52-week high earlier in the session.The biotechnology company said the milestone marks the first clinical evaluation of its liver franchise.The company also announced that the Food and Drug Administration has granted rare pediatric disease designation to PM577 for Wilson disease.The Phase 1/2 clinical trial is an open-label, global, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease containing at least one p.H1069Q allele in the ATP7B gene.The company said the study will initially enroll adults who are clinically stable on standard-of-care therapy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673700937","title":"Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673700937","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673700937?lang=en_us&edition=fundamental","pubTime":"2026-10-05 21:14","pubTimestamp":1791206063,"startTime":"0","endTime":"0","summary":"Prime Medicine  has dosed its first patient in a phase 1/2 clinical trial of PM577a, an investigational in vivo treatment for H1069Q-mutated Wilson disease, the company said Monday.The study will initially enroll adults who are clinically stable and being treated with standard-of-care therapy, the company said.Initial clinical data are expected next year, the company added.The biotechnology company also said the US Food and Drug Administration has granted Rare Pediatric Disease designation to PM577 for Wilson disease.Wilson disease is a rare, progressive genetic disorder which leads to copper accumulation in the liver, followed by damage to other organs, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702916","title":"Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of Pm577a for H1069q-Mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702916?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUABYJKHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702419","title":"Prime Medicine, - Initial Clinical Data from Pm577a Trial Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702419?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUABYJKHT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673415702","title":"Prime Medicine, - Pm577 Granted Rare Pediatric Disease Designation by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673415702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673415702?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nTUABYJKHT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670298004","title":"Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670298004","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670298004?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:12","pubTimestamp":1790356322,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) cleared a key regulatory hurdle as the Food and Drug Administration approved the start of human testing for PM647, a treatment for alpha-1 antitrypsin deficiency, a genetic disea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447282","title":"Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447282","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447282?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:19","pubTimestamp":1790338740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670445505","title":"Costco Wholesale, Scholastic and 3 Stocks to Watch Heading Into Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2670445505","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670445505?lang=en_us&edition=fundamental","pubTime":"2026-09-25 15:24","pubTimestamp":1790321041,"startTime":"0","endTime":"0","summary":"Scholastic fell on weak results, Costco beat estimates, Prime Medicine gained on FDA clearance, and INLIF surged on revenue growth.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/09/61989165/costco-wholesale-scholastic-and-3-stocks-to-watch-heading-into-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2381873111.SGD","LU0943347566.SGD","LU0238689110.USD","LU1116320737.USD","LU1551013342.USD","BK4213","LU1066051811.HKD","LU2168564495.EUR","COSW","LU1923622614.USD","LU1496350171.SGD","TRUO","LU0234572021.USD","BK4581","COTG","UGE","LU2360106947.USD","LU0079474960.USD","INLF","LU2168564222.USD","XLP","LU1069344957.HKD","FSTA","IE00BKVL7J92.USD","PRME","BK4585","LU0385154629.USD","LU2237438978.USD","LU1066051498.USD","BK4504","LU1116320901.HKD","IE00BZ1G4Q59.USD","RTH","LU0820561818.USD","LU2095319765.USD","LU2125154778.USD","IE00B5TLWC47.USD","LU0689472784.USD","BK4588","LU2125909247.SGD","LU0256863811.USD","LU1066051225.USD","LU2433249047.HKD","LU1496350502.SGD","LU2125154935.USD","LU0471298694.HKD","LU0823434583.USD","LU2125909593.SGD","BK4161","LU1571399168.USD","LU0265550359.USD","SCHL","BK4596","COST","LU0417517546.SGD","BK4533","HK0000819398.USD","BK4550","BK4139","LU0820561909.HKD","LU2360032135.SGD","LU2168564065.EUR","LU0265550946.USD","LU0823434740.USD","BK4155","LU1066053197.SGD","TBN","LU2097829019.USD","LU0234570918.USD","LU2210149790.SGD","LU1551013425.SGD","BK4111","LU1035775433.USD","LU2168563687.JPY","LU2210150020.SGD","IE0008368304.USD","LU2168564149.EUR","LU1323610961.USD","LU0471298777.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412701","title":"Chardan Capital Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412701","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412701?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:35","pubTimestamp":1790307314,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Keay Nakae maintained a Buy rating on Prime Medicine, Inc. yesterday and set a price target of $7.00. According to TipRanks...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670726415","title":"Stocks to Watch: Akamai, Scholastic, Prime Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2670726415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670726415?lang=en_us&edition=fundamental","pubTime":"2026-09-25 06:46","pubTimestamp":1790289960,"startTime":"0","endTime":"0","summary":"Akamai Technologies struck an $11.6 billion deal with Anthropic for its computing services. Shares rallied 22% to $134.88 in after-hours trading Thursday.Scholastic logged lower sales in its first fis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","AKAM","SCHL","BK4111","BK4116","BK4139","AKAL","LU1059921491.USD","BK4554","LU2286300806.USD","BK4608","BK4585","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670151394","title":"Analysts Are Bullish on Top Healthcare Stocks: Arcus Biosciences (RCUS), Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670151394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670151394?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:50","pubTimestamp":1790286610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcus Biosciences (RCUS) and Prime Medicine, Inc. (P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-arcus-biosciences-rcus-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-arcus-biosciences-rcus-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","HCSG","BK4585","LU0128526141.USD","BK4137","LABU","PRME","RCUS","XBI","BK4139","BK4581","LU0029874061.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670139964","title":"Prime Medicine Shares Jump on FDA Clearance for Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2670139964","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670139964?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:08","pubTimestamp":1790284080,"startTime":"0","endTime":"0","summary":"Shares of Prime Medicine jumped after the biotechnology company said the Food and Drug Administration cleared its investigational new drug application for PM647 to treat the genetic disease Alpha-1 Antitrypsin Deficiency.Shares were up 13% to $3.47 in after-hours trading on Thursday after closing down 1.9% at $3.07. Through the close, the stock had fallen 12% this year.The company said the FDA's clearance means it can initiate clinical studies in the U.S.\"FDA clearance of the PM647 IND is an important milestone for Prime Medicine, marking continued momentum across our liver franchise,\" Chief Executive Officer Allan Reine said. \"PM647 has the potential to change how AATD is treated, offering a Prime Editing-based approach that moves beyond protein replacement and targets the root cause of disease.\"","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","PRME","BK4139","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670629418","title":"Prime Medicine announces FDA clearance of IND application for PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2670629418","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670629418?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:05","pubTimestamp":1790280337,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) announced that the FDA has cleared the company’s Investigational New Drug, or IND, application for PM647, an investigational ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-announces-fda-clearance-of-ind-application-for-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","LABU","PRME","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670549005","title":"Prime Medicine Wins FDA IND Clearance for PM647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670549005","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670549005?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280081,"startTime":"0","endTime":"0","summary":"Prime Medicine wins FDA IND clearance for PM647 in alpha-1 antitrypsin deficiencyPrime Medicine secured FDA clearance for an IND for PM647, an in vivo prime editor for alpha-1 antitrypsin deficiency.C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL5tThl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4585","BK4588","IE00BQXX3C00.GBP","SG9999014021.USD","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","NDAQ","BK4112","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BQXX3F31.USD","PRME","BCDF","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670749070","title":"Prime Medicine, - Initial Clinical Data for Pm647 Expected in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2670749070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670749070?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA3ZFFJ5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670549070","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for Pm647 in Alpha-1 Antitrypsin Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2670549070","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670549070?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nTUA3ZFFJ5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871296","title":"Prime Medicine Set for Fireside Chats at H.C. Wainwright, Morgan Stanley Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871296","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871296?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:02","pubTimestamp":1788436978,"startTime":"0","endTime":"0","summary":"Prime Medicine set for fireside chats at H.C. Wainwright, Morgan Stanley healthcare conferencesPrime Medicine management schedules investor meetings at the Wells Fargo 21st Annual Healthcare Conferenc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL7XkcrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1668664300.SGD","IAI","LU1791710582.SGD","LU1720051108.HKD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","LU0912757837.SGD","LU1244550494.USD","LU0390134368.USD","LU1791710400.SGD","LU1720051017.SGD","LU2111349929.HKD","IE00BN0W2W23.USD","LU2028103732.USD","LU0314104364.USD","BK4581","BK4139","IE00BGHQF748.EUR","LU1244550221.USD","LU0098860793.USD","LU0795875169.SGD","LU2089284900.SGD","IE00B64PRP62.GBP","LU0557290698.USD","LU0882574139.USD","NDAQ","LU0225283273.USD","LU1363072403.SGD","LU2133065610.SGD","LU2264538146.SGD","SG9999014021.USD","KBWB","LU0210528500.USD","LU1548497426.USD","LU1732800096.USD","IE00BZ1G4Q59.USD","LU0158827948.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU1074936037.SGD","LU1988902786.USD","LU0106831901.USD","BCDF","LU2023251221.USD","SG9999014039.USD","LU0053666078.USD","LU2210150020.SGD","PRME","LU2095319765.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662734464","title":"Prime Medicine Price Target Maintained with a $7.00/Share by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2662734464","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662734464?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:15","pubTimestamp":1787660100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784346","title":"Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784346","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784346?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:25","pubTimestamp":1787642725,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Keay Nakae maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $7.00. According to TipRanks, Na...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-reaffirms-their-buy-rating-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658075987","title":"Prime Medicine Price Target Maintained with a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658075987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658075987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:35","pubTimestamp":1786358100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":-0.1508},{"period":"1month","weight":0.2714},{"period":"3month","weight":0.4448},{"period":"6month","weight":0.3863},{"period":"1year","weight":0.0114},{"period":"ytd","weight":0.2824}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.75,"avgChangeRate":0.248413},{"month":7,"riseRate":0.75,"avgChangeRate":0.106402},{"month":8,"riseRate":0.25,"avgChangeRate":-0.065687},{"month":9,"riseRate":0.25,"avgChangeRate":0.046401},{"month":10,"riseRate":0.5,"avgChangeRate":0.029896},{"month":11,"riseRate":0.2,"avgChangeRate":-0.08079},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction